ABIVAX vs Alkermes

ABIVAX (ABVX), health care, and Alkermes (ALKS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Alkermes is worth $7.6B on the stock market and ABIVAX $7.3B: Alkermes is valued at 5% more. Over the past year ABIVAX's share price has moved -26.5% and Alkermes's +59.0%.

Key facts

ABIVAX market value
$7.3B
Alkermes market value
$7.6B
Alkermes revenue
$1.5BFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

ABIVAX vs Alkermes: every measure side by side
Measure ABIVAX Alkermes
SectorHealth CareHealth Care
Country France Ireland
Fiscal year ends2025-12-312025-12-31
Size
Market cap$7.3Blower$7.6Bhigher
Revenue—$1.5B
Earnings-$372.9Mlower$241.7Mhigher
Employees98lower2,050higher
Total assets$648.3Mlower$2.5Bhigher
Valuation
P/E——
P/S—5.2
P/B——
Dividend yield——
Profitability
Operating margin—17.2%
Balance sheet
Net assets$505.1Mlower$1.8Bhigher
Total liabilities$143.3Mlower$667.7Mhigher
Total debt——
Cash on hand$573.3Mhigher$388.6Mlower
Price change
Today-0.58%higher-2.41%lower
1 year-26.5%lower+59.0%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (1)

ABIVAX only (3)

Percentages are each holding's share of that investor's reported portfolio (under "Both": ABIVAX / Alkermes). Who owns ABVX · Who owns ALKS

Further comparisons

Learn

Questions and answers

Which is bigger, ABIVAX or Alkermes?

By market value, Alkermes is the larger: $7.6B against $7.3B for ABIVAX.

Which superinvestors own both ABIVAX and Alkermes?

In their latest 13F filings, Doug Silverman holds both.

Cite this page

Funkfolio, “ABIVAX vs Alkermes”, data as of 17 November 2026. https://funkfolio.com/compare/abvx-vs-alks

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.